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Abstract
Background: Amplification and cloning of naïve T cell Receptor (TR) repertoires or antigen-
specific TR is crucial to shape immune response and to develop immuno-based therapies. TR
variable (V) regions are encoded by several genes that recombine during T cell development. The
cloning of expressed genes as large diverse libraries from natural sources relies upon the availability
of primers able to amplify as many V genes as possible.
Results: Here, we present a list of primers computationally designed on all functional TR V and J
genes listed in the IMGT®, the ImMunoGeneTics information system®. The list consists of
unambiguous or degenerate primers suitable to theoretically amplify and clone the entire TR
repertoire. We show that it is possible to selectively amplify and clone expressed TR V genes in
one single RT-PCR step and from as little as 1000 cells.
Conclusion: This new primer set will facilitate the creation of more diverse TR libraries than has
been possible using currently available primer sets.
Background
The T cell receptor (TR) is a complex of trans-membrane
dimeric proteins that mediate the antigen-dependent acti-
vation of T cells [1]. TR recognize self-MHC molecules
presenting 'foreign-looking' protein fragments on the sur-
face of infected, cancerous or 'non-self' cells. Most of cir-
culating T cells express TR comprising of alpha and beta
chains, while a minimal portion express the gamma and
delta dimers [2]. Each chain consists in its extracellular
region of a variable (V) and a constant (C) domain. Like
immunoglobulin (IG), TR are encoded by several genes
that undergo somatic recombination during T cell devel-
opment [3]. According to the sequences deposited in
IMGT®, the ImMunoGeneTics information system®, http:/
/imgt.cines.fr, [4-6], the human TRA locus has 47 TRAV,
50 TRAJ and 1 TRAC genes, whereas the TRB locus has 54
TRBV, 2 TRBD, 14 TRBJ and 2 TRBC genes; the TRD locus
has 3 TRDV, 3 TRDD, 4 TRDJ and 1 TRDC genes, whereas
the TRG locus has 9 TRGV, 5 TRGJ and 2 TRGC genes.
The hypervariable regions, known as complementarity
determining regions (CDR), define antigen-binding spe-
cificities the CDR1 and CDR2 being encoded by the V
genes whereas the CDR3 result from V-(D)-J recombina-
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tions. The combinatorial rearrangement of the V, (D) and
J genes and the mechanisms of trimming and N addition
accounts for the huge diversity of naïve TR and T cell rep-
ertoires.
Defining the TR gene usage in antigen-activated T cells is
crucial for shaping the immune response in several phys-
iological and pathological conditions such as inflamma-
tion and infectious diseases. Furthermore, the cloning of
antigen-specific TR is emerging as a powerful strategy for
immune-based therapies in autoimmunity, cancer and
vaccination [7,8]. However, cloning and expression of
specific TR is still a difficult task. TR has an intrinsic low
affinity for its antigen and, as membrane-bound protein,
is poorly stable when expressed as recombinant soluble
protein. Working on the variable portion of few well
defined TR, several authors have reported methods to
overcome these problems [9]. Soluble and stable TR have
been expressed as single-chains [10], or fused to a coiled
coil heterodimerization motif [11] or introducing non
native disulphide bond [12]. The affinity of specific TR
molecules to their antigens has been improved to picomo-
lar levels either by phage [13] or Yeast [14] display meth-
ods.
Different methods have been proposed to investigate TR
repertoire including length analysis of TR complementa-
rity-determining region 3 (CDR3), flow cytometry, and
immuno-histochemistry [15].
The availability of the IMGT/GENE-DB database [5] com-
prising all germline genes has fuelled the development of
several PCR-based methods for cloning TR repertoires.
However, the cloning and analysis of TR is rendered diffi-
cult by the diversity of the 5' V gene sequences and by the
repertoire complexity. Several authors have reported sets
of primers that allow PCR-mediated amplification of V
regions [16-19]. However, these primers have been
designed to amplify subsets of TR genes or have been used
in the analysis of clonal T cell populations [20].
Here we report a novel set of primers predicted to amplify
nearly 100% of all functional TR V genes. We show that
these primers can amplify transcribed TR V genes from as
little as 1000 peripheral blood T cells, allowing a reliable
and efficient method to clone TR repertoires.
Results
Data analysis and primers design
The creation of large diverse libraries representing the spe-
cificities of TR repertoires relies on primers which are able
to amplify all sequences coding for functional variable
regions. With this aim, we developed a strategy to design
a new set of primers that greatly reduces the number of
reactions needed to amplify all functional V sequences.
Germline V, D and J gene sequences encoding TRA, TRB,
TRD and TRG chains [5,6], were retrieved from the IMGT®
information system http://imgt.cines.fr. Two algorithms,
"TCRAlignment" and "TCROligo" (see M&M), have been
developed to analyze 47 TRAV, 54 TRBV, 9 TRGV, 3 TRDV,
50 TRAJ, 14 TRBJ, 5 TRGJ and 4 TRDJ genes. In the first
step sequences belonging to each data set were grouped
into "families" by the TCRAlignment algorithm. The algo-
rithm performs an alignment limited to the first 23 bases
of FR1 at the 5' end of each V region sequence (starting at
base number 1) or in the last 23 bases, at the 3' end in the
case of J genes and group them on the basis of similarities.
Sequences are grouped if they share less than two mis-
matches within the 3' 16 bases. This criteria is applied to
either 23, 22, 21, 20 or 19 bases long sequences. In the
second step the TCROligo algorithm uses these sequence
families to design unique or degenerated primers (see
M&M) for both the V or J region. With these tools we gen-
erated a novel set of primers (Table 1 and 2) that makes
theoretically feasible the amplification and cloning of the
entire TR repertoire. The variable regions of all functional
TRA and TRB chains can be in silico amplified by 25 and
17 reactions, respectively, while 4 primer pairs are needed
to amplify the 9 TRGV genes (Table 1). We also obtained
a reduced set of primers for the poor similar J genes (Table
2), being 39 primer pairs sufficient to amplify 50 TRAJ
genes and 9 primer pairs for 14 TRBJ genes.
RT-PCR
To check whether the primers designed in silico were suit-
able to clone TR specificities, we performed RT-PCR with
all the Forward primers for TRAV, TRBV, TRDV and TRGV.
Each TR V primer was paired with an unique primer
annealing to the 5' end of the TR C genes (Table 3). RT-
PCR reactions were carried out on total RNA from periph-
eral blood T lymphocytes. For each reaction cDNA corre-
sponding to approximately 1000 cells was used. As shown
in figure 1 all the reactions of the TRAVfor primers pro-
duced PCR fragments of the expected size, the only excep-
tion being the TRAV7for and the TRAV18for primers. A
specific TRAV7for amplification could be obtained after a
second round of amplification of the first reaction. The
TRAV18for primer gave a band with a lower size than
expected. The TRBVfor amplifications were all positive
with the expected size the only exception being the
TRBV30for that could be seen after reamplification of the
first reaction. Finally we got amplifications for four TRDV
and TRGV for primer pairs.
To confirm the specificity of the amplification products,
each PCR fragment for TRVAfor and TRVBfor amplifica-
tions was purified, blunt-cloned and independently used
to transform E. coli cells. Several random clones from each
transformation were sequenced and the results are sum-
marized in Table 4. The TR database analysis of theBMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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Table 1: TR V Region Forward primers
OLIGO NAME OLIGO SEQUENCE TRA V GENES OPTIMALLY RECOGNIZED
ALPHA
TRAV1for GGA CAA ARC MTT GAS CAG CC V1-1,V1-2
TRAV2for AAG GAC CAA GTG TTT CAG CC V2
TRAV3for GCT CAG TCA GTG RCY CAG CC V3, V8-3
TRAV4for GAT GCT AAG ACC ACM CAG CC V4, V26-1, V26-2
TRAV5for AGA AAA SAW STG GAG CAG AGT C V5, V10, V22, V34, V41
TRAV6for AGC CAA AAG ATA GAA CAG AA V6
TRAV7for GAA AAC CAG GTG GAG CAC AG V7
TRAV8for GCC CAG TCK GTG ASC CAG CW V8-1, V8-2, V8-4, V8-6, V8-7
TRAV9for GGA AAT TCA GTG RYC CAG AY V9-1, V9-2
TRAV12for CAG AAG GAG GTG GAG CAG RAT YC V12-1, V12-2, V12-3
TRAV13for GGA GAG ART GTG GRG CWG CA V13-1, V13-2
TRAV14for GCC CAG AAG RTW ACT CAA RC V14/DV4, V19
TRAV16for GCC CAG ASA GTS ACT CAG YC V16, V38-1, V38-2/DV8
TRAV17for AGT CAA CAG GGA GAA GAG GA V17
TRAV18for GGA GAC TCG GTT ACC CAG AC V18
TRAV20for AAA CAG GAG GTG ACG CAG AKT CC V20, V21
TRAV23for GGC CAA CAG AAG GAG AAA AG V23/DV6
TRAV24for GAG CTG AAM GTG GAA CAA AR V24, V39
TRAV25for GGA CAA CAG GTA ATG CAA AT V25
TRAV27for ACC CAG CTG CTG GAG CAG AG V27
TRAV29for AGT CAA CAG AAG AAT GAT GA V29/DV5
TRAV30for CAA CAA CCA GTG CAG AGT CC V30
TRAV35for GGT CAA CAG CTG AAT CAG AG V35
TRAV36for GAA GAC AAG GTG GTA CAA AG V36/DV7
TRAV40for AGC AAT TCA GTC AAG CAG AC V40
BETA TRBV GENES OPTIMALLY RECOGNIZED
TRBV2for GAT GCT GAA GTC RCM CAG ACT CC V2, V16, V23-1
TRBV3for GAT GCW GMT GTT WCC CAG AC V3-1, V24-1
TRBV4for GAC ACT GRA GTY ACS CAG ACA CC V4-1, V4-2, V4-3, V12-5
TRBV5for GAG GCT GGA GTC ACH CAA AS V5-1, V5-3, V9, V5-4, V5-5, V5-6, V5-7, V5-8
TRBV6for GAG CCT GGW GTC ASY CAG AC V6-1, V6-2, V6-3, V6-5, V6-6, V6-7, V6-8, V6-9,V17
TRBV7for GGT GCT GGA GTY KCC CAG W V7-1, V7-2, V7-3, V11-2, V7-4, V7-6, V7-7, V7-8, V7-9
TRBV10for GAT GCT GRR ATC ACC CAG R V6-4, V10-1, V10-2, V10-3
TRBV11for GAA GCT GAA GTT GCC CAG TC V11-1
TRBV13for GAT GCT GGA GTY ATC CAG TC V13, V12-3, V12-4
TRBV14for GAA GCT GGA GTK RYT CAG T V11-3, V14
TRBV15for GAT GCC ATG GTC ATC CAG AA V15
TRBV18for AAT GCC GGC GTC ATG CAG AA V18
TRBV19for GAT GGT GGA ATC ACT CAG TC V19
TRBV20for AGT GCT GTC RTC TCT CAA MA V20-1, V29-1
TRBV25for GAA GCT GAC ATC TAC CAG AC V25-1
TRBV27for GAT GTG AAA GTR ACC CAG ARC YC V27, V28
TRBV30for ACA CTC CAG GCA CAG AGA TA V30
GAMMA TRGV GENES OPTIMALLY RECOGNIZED
TRGV1for TCT TCC AAC TTG GAA GGG RG V1, V2, V3, V4, V5, V8
TRGV9for GCA GGT CAC CTA GAG CAA CC V9
TRGV10for TTA TCA AAA GTG GAG CAG TT V10
TRGV11for CTT GGG CAG TTG GAA CAA CC V11
DELTA TRDV GENES OPTIMALLY RECOGNIZED
TRDV1for GCC CAG AAG GTT ACT CAA GC V1
TRDV2for GCC ATT GAG TTG GTG CCT GA V2
TRDV3for TGT GAC AAA GTA ACC CAG AG V3
List of optimal primer sequence as designed with the TCRAlignment and TCROligo algorithms for the TRAV, TRBV, TRGV and TRDV genes.BMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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sequenced clones show that non-degenerate primers
matching unambiguously to single TR genes selectively
amplify their specific single gene targets. This specific
amplification could be achieved even for very rare genes.
For example the TRBV18for or TRBV11for primers selec-
tively amplify the TRBV18 and TRBV11-1 genes that are
found in 0.5% or 0.8% of circulating T cells [21], respec-
tively.
Furthermore when analyzing clones deriving from degen-
erate primers, matching to a subset of TR clonotypes, we
show that although sequencing a relative low number of
clones, a high percentage of all possible genes were
present. For example among 5 members present in the
respective groups the TRAV5for or TRAV8for primers
amplify 3 genes, as well the TRBV4for or TRBV5for prim-
ers amplify 3 out of 4 and 5 out of 8 genes present in the
group, respectively. Interestingly, some genes amplified
by degenerate primers are more frequent than other group
members. This finding is likely due to the relative abun-
dance of these transcripts within the analysed repertoires
and not to amplification biases since there is no obvious
relationship between primer and gene sequences.
Finally it is worth noting that some degenerate primers are
also able to amplify genes that have not been computa-
tionally scored as targets (Table 1). In the case of the
TRBV2for the amplified genes present only 3 to 5 base dif-
ferences with the primers but were excluded in the first
step of "families" generation for the presence of mis-
matches in the first 16 bases. The same is true for the
TRBV6for primer that amplify TRBV2 gene that present
only 2 nucleotides different form the primer, with one in
the first 16. Although this might limit the usefulness of the
primer set described for clonotypic analyses this ability
increases considerably the chances to clone most TR tran-
scripts, if not all, and turns out very useful for the creation
of libraries representative of TR repertoires.
V region Restriction enzymes analysis
The primer sets presented in this work consent the cloning
of virtually the entire repertoire of TR molecules in library
vectors. In the view of the creation of large TR libraries we
have also analysed the frequency of restriction enzymes
cutting in the database of the downloaded TR V, J and D
genes. We selected 27 restriction enzymes usually used for
molecular cloning and the corresponding recognition
sites were used to compute a restriction map for each of
our data set by employing a simple PERL program. The
output is shown in Table 5 and evidences the presence of
7 enzymes (AscI, BssHII, NheI, NotI, SfiI, SacI, SalI) not
cutting in any of the regions considered. These restriction
enzymes could therefore be used for individual T cell or
library cloning in order to avoid the loss of specific TC
genes during the cloning process. Restriction sites would
be added directly to the oligonucleotides based on a strat-
egy previously described for both antibody and TC V
region cloning and expression [7,22,23] that involves
cloning of the engineered genes (antibody or TC V) after a
leader sequence, for both bacterial (eg pelB, OmpA,
phoaA) or eukaryotic (Igleader) soluble expression.
Discussion
The availability of databases comprising gene sequences
encoding all IG or TR genes (IMGT/GENE-DB)[5] has
allowed the PCR-mediated cloning of antibody reper-
toires or subsets of TR and has shed light over the immune
response in human and mouse.
Furthermore, the engineering of synthetic antibodies has
become an important methodology for the generation of
reagent, diagnostic and therapeutic molecules. Obviously,
the availability of databases listing all TR genes has been
seen by researchers as an opportunity to do on TR what
has been done with immunoglobulins. However, the
cloning of TR repertoires has been hampered by a consid-
erable higher diversity of 5' TR V genes. Several primer sets
have been reported so far, but these have allowed the
amplification and cloning of a restricted group of TR
genes, mostly belonging to the alpha and beta chains, or
have been used for the analysis of clonal T cell popula-
tions [16-19].
Here, we report a new set of primers that allow the theo-
retical amplification and cloning of all TR V genes. The
primers were computationally designed on sequence data
available at the IMGT® information system, and compris-
ing genes for all functionally synthesized TR chains. The
criteria we adopted for algorithm design were such to pro-
vide the least number of primers required to amplify all
catalogued genes. We obtained a number of primers con-
siderably lower than those reported by other authors
[17,19,20]. For instance, the number of primers required
to amplify all V regions of TRA and TRB chains is 25 and
17, respectively, instead of 45 and 43 for each of the two
amplification rounds reported by Boulter and colleagues
[20].
Using two representative sets of primers matching either
to single or to a subset of TR genes, we show that they can
efficiently amplify target genes in one RT-PCR step, and
from as little as 1000 T cells without the need of further
amplifications. Among all random sequenced clones, we
did not find no-TR gene sequences, a finding that con-
firms the selectivity of our primers. In agreement with
data demonstrating the biased composition of TRA and
TRB repertoires [15], we found that degenerated primers
amplify with higher frequency some members of target
group.BMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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Table 2: TR J gene reverse primers
OLIGO NAME OLIGO SEQUENCE J GENES OPTIMALLY RECOGNIZED
ALPHA
TRAJ6rev CGG ATG AAC AAT AAG GCT GGT TC J6
TRAJ10rev GAG TTC CAC TTT TAG CTG AG J10
TRAJ11rev TGG AGA GAC TAG AAG CAT AG J11
TRAJ12rev TGG ACT GAC CAG MAG TCK GG J12, J8
TRAJ13rev TGG GAT GAC TTG GAG CTT TG J13
TRAJ15rev GGA ACT CAC TGA TAG GTG GG J15
TRAJ16rev AAG ATC CAC CTT TAA CAT GG J16
TRAJ17rev TGG TTT AAC TAG CAC CCT GG J17
TRAJ20rev TGC TCT TAC AGT TAC TGT GG J20
TRAJ21rev TGG TTT TAC ATT GAG TTT GG J21
TRAJ22rev AGG CCA RAC AGT CAA YTG WGT J22, J18
TRAJ23rev GGG TTT CAC AGA TAA CTC CG J23
TRAJ25rev TGG TAT GAC CAC MAC YTG GKT J25, J7
TRAJ26rev GGG CAG CAC GGA CAA TCT GG J26
TRAJ27rev TGG CTT CAC AGT GAG CGT AG J27
TRAJ29rev TGC TTT MAC ARA WAG TCT TGT J29, J9
TRAJ30rev GGG GAG AAT ATG AAG TCG TG J30
TRAJ31rev GGG CTT CAC CAC CAG CTG AG J31
TRAJ32rev TGG CTG GAC AGC AAG CAG AG J32
TRAJ33rev TGG CTT TAT AAT TAG CTT GG J33
TRAJ34rev TGG AAA GAC TTG TAA TCT GG J34
TRAJ37rev TGG TTT TAC TTG TAA AGT TG J37
TRAJ38rev CGG ATT TAC TGC CAG GCT TG J38
TRAJ40rev TGC TAA AAC CTT CAG CCT GG J40
TRAJ41rev GGG TGT GAC CAA CAG CGA GG J41
TRAJ42rev TGG TAT GAC MGA GAG TTT RGT SC J42, J28
TRAJ44rev TGG TTG CAC YTG RAG TCT TGT TC J44, J5
TRAJ45rev GGG CTG GAT GAT TAG ATG AG J45
TRAJ46rev GGG CCT AAC TGC TAA ACG AG J46
TRAJ47rev GGA CTT GAC TCT CAG AAT GG J47
TRAJ48rev TGG CCG GAT GST GAG TCT KGT YC J48, J3
TRAJ36rev GGG AAT AAY GGT GAG TCT YGT TC J48, J36
TRAJ49rev GGG TTT GAC CRT YAA MCT TGT J49, J39
TRAJ50rev AGG TTT TAC TGA TAA KCT TGT CC J50, J14
TRAJ52rev TGG ATG GAC AGT CAA GAT GG J52
TRAJ53rev TGG ATT CAC GGT TAA GAG AG J53
TRAJ54rev TGG GTG TAY AGY CAG CCT GGT YC J54, J4
TRAJ56rev TGG TCT AAC AC TCA GAG TTA J56
TRAJ57rev TGG TTT TAC TGT CAG TYT SG J57, J43
BETA
TRBJ1rev TGT GAC YGT GAG YCT GGT GC J1-1, J2-7
TRBJ2rev TGT CAC RGT KAR CCT GGT CC J1-2, J1-6
TRBJ3rev TAC AAC AGT GAG CCA ACT TC J1-3
TRBJ4rev CAG CAC WGA GAG CYG GGT YC J1-4, J2-4
TRBJ5rev TAG GAT GGA GAG TCG AGT CC J1-5
TRBJ2.1rev TAG CAC TGT SAG CCG KGT SCC TG J2-1, J2-3
TRBJ2.2rev CAG AAC CAG GAG TCC TCC GC J2-2P
TRBJ2.6rev CAG TAC GGT CAG CCT RSW GC J2-2, J2-6
TRBJ2.5rev GAG CAC CAG GAG CCG CGT GCC TG J2-5
GAMMA
TRGJP1rev AGG CGA AGT TAC TAT GAG CY JP1,JP2
TRGJPrev TGT AAT GAT AAG CTT TGT TC JP
TRGJ1rev TGT GAC AAC MAG TGT TGT TC J1,J2
DELTA
TRDJ1rev TGG TTC CAC GAT GAG TTG TG J1
TRDJ2rev TGG TTC CAC AGT CAC ACG GG J2
TRDJ3rev GGG CTC CAC GAA GAG TTT GA J3
TRDJ4rev TTG TTG TAC CTC CAG ATA GG J4
List of optimal primer sequence as designed with the TCRAlignment and TCROligo algorithms for the TRAJ, TRBJ, TRDJ and TRGJ genes.BMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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Conclusion
Our purpose was to create a primer set able to optimally
amplify all TR V genes, and we feel that we have done this.
This set will allow the profiling of TR repertoire as well as
the creation of libraries such as those based on single
chain formats (scTR). Furthermore, the use of this set will
facilitate the cloning of antigen-specific TR, a prerequisite
for the development of immune-based therapies in
autoimmunity, cancer and vaccination.
Methods
Sequences encoding TR V regions
Sequences corresponding to the functional V and J genes
for TR alpha, beta, gamma and delta chains [4] were
downloaded from IMGT ® http://imgt.cines.fr. 47 TRAV,
54 TRBV, 9 TRGV, 3 TRDV, 50 TRAJ, 14 TRBJ, 5 TRGJ and
4 TRDJ genes sequences were retrieved to constitute our
working data set.
Primers Design
We designed two algorithms: "TCRAlignment", which clus-
ters either V or J sequences on the basis of DNA similari-
ties; "TCROligo", which defines the primer set for each
cluster. The parameters considered to design the algo-
rithms were the following:
- the Forward (For) primer must anneal at the 5' end of TR
V genes starting at the first base.
- the Reverse (Rev) primer must anneal at the 3'-end of TR
J gene ending at the last base.
- primer length must range 19 to 23 nucleotides;
- AT content in the range of 35–65%;
- all scored primers must perfectly anneal to the last 3'-end
16 bp;
Table 3: TR C genes reverse primers
OLIGO NAME OLIGO SEQUENCE C GENE RECOGNIZED
TRACrev TCTCAGCTGGTACACGGCAG TRAC
TRBCrev AGATCTCTGCTTCTGATGGCTC TRBC2
TRGCrev GAAGGAAGAAAAATAGTGGGC TRGC2
TRDCrev GGATGGTTTGGTATGAGGCTG TRDC
List of reverse primer sequence for TR constant regions
Primer validation by RT-PCR Figure 1
Primer validation by RT-PCR. All For primers listed in Table 1 were used together with common TR Crev primer (Table 3). 
Specific amplification could be seen for all primers used the only exceptions being TRAV7for, TRAV18 for and TRBV30for 
were positive amplification could be obtained after a second round of amplification of the first reaction.BMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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- degenerate nucleotides are introduced at no more than
three positions so that the total number of different vari-
ants is less than eight, and only if it helps for full homol-
ogy at the 3'-end 16 bp.
The  TCRAlignment  algorithm stores the first 23 nucle-
otides of each data set sequence in a N × M matrix, where
N is the number of considered sequences and M is equal
to 23 (maximum primer length), and generates an align-
ment by comparing the first reference sequence to the oth-
Table 4: TR V primers validation
OLIGO NAME TRAV GENES OPTIMALLY RECOGNIZED others found N
Experimentally found Experimentally Not found
TRAV1for V1-2 V1-1 - 2
TRAV2for V2 - - 5
TRAV3for - V3, V8-3 - -
TRAV4for V26-1 V4, V26-2 - 2
TRAV5for V10, V34, V41 V5, V22 - 12
TRAV6for V6 - - 3
TRAV7for V7 - - 2
TRAV8for V8-1, V8-4, V8-6 V8-2, V8-7 - 13
TRAV9for V9-1 V9-2 - 2
TRAV12for V12-1 V12-2, V12-3 - 2
TRAV13for V13-1, V13-2 - - 2
TRAV14for V19 V14/DV4 TRDV1 4
TRAV16for V16 V38-1, V38-2/DV8 TRB11-3 3
TRAV17for V17 - - 3
TRAV18for V18 - - 1
TRAV20for V20, V21 - - 5
TRAV23for V23/DV6 - - 5
TRAV24for V24- V39 V6 1
TRAV25for V25 - - 2
TRAV27for V27 - - 1
TRAV29for V29/DV5 - 18-1 2
TRAV30for V30 - - 1
TRAV35for V35 - - 1
TRAV36for V36/DV7 - - 1
TRAV40for V40 - - 1
TRBV GENES OPTIMALLY RECOGNIZED others found N
Experimentally found Experimentally Not found
TRBV2for V2, V23-1 V16 V6-5, V7-6, V12-5, V24-1 10
TRBV3for V3-1, V24-1 - - 2
TRBV4for V4-1, V4-3, V12-5 V4-2 - 4
TRBV5for V5-1, V5-4, V5-5, V5-6, V5-7 V5-3, V9, V5-8 - 7
TRBV6for V6-1, V6-2, V6-5 V6-3, V6-6, V6-7, V6-8, V6-9, V17 V2 5
TRBV7for V7-1, V7-2, V7-3, V7-4 V7-6, V7-7, V7-8, V7-9, V11-2 - 7
TRBV10for V6-4 V10-1, V10-2, V10-3 - 1
TRBV11for V11-1 - - 4
TRBV13for V12-3 V13, V12-4 7
TRBV14for V14 V11-3 V11-2 3
TRBV15for V15 - - 2
TRBV18for V18 - - 5
TRBV19for V19 - - 2
TRBV20for V29-1 V20-1 - 3
TRBV25for V25-1 - - 1
TRBV27for V28 V27 - 5
TRBV30for V30 - - 1
Primer specificity validation by DNA sequencing. PCR products (see Fig. 1) were cloned in pTZ57R/T vector and up to thirteen clones randomly 
selected and sequenced. N = number of sequenced clonesBMC Immunology 2008, 9:50 http://www.biomedcentral.com/1471-2172/9/50
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ers. Then, the algorithm scores the alignment for
sequences that differ from the first one at 1 or 2 nucle-
otides in the 3'end 16 bases and clusters them in a family.
This criteria guarantees full homology in the 3'end region.
In order to group the large amount of similar sequences,
the algorithm changes the M value by considering the four
possible primer lengths (23, 22, 21, 20, 19). After count-
ing for each length the number of homologies in the last
16 positions of each aligned sequence, the algorithm
chooses, according to the previous criteria, the M value for
which the number of clustered sequences is the greatest.
The alignment of selected sequences is saved and the
entire procedure is repeated for the remaining sequences.
For each TCRAlignment family, the TCROligo algorithm
designs a primer complementary to all sequences grouped
in the family. Each alignment is saved in a N × M matrix,
and the algorithm designs a primer by considering each
position of the alignment, that is each column of the
matrix, and by filling the corresponding position of the
primer as follows: for each of the first M-16 positions,
where M can assume the four possible primer lengths val-
ues, the algorithm puts the nucleotide that appears most
frequently in the considered column while in the last 16
positions it inserts, where necessary, degenerate nucle-
otides. Once the primer was designed, TCROligo  algo-
rithm computes its AT content and if it is not comprised
between 35% and 65% the first M-16 bases of the primer
are changed.
By applying this procedure to all the alignments found
with the previous program we find the primers for all the
functional TR V and J genes.
Common reverse primers were designed in the first exon
for all the constant region and are reported in table 3
RT-PCR
Peripheral-blood monocites cells (PBMC) were isolated
from healthy donors by density gradient centrifugation
(Ficoll-Paque PLUS, GE Healthcare, Milan, Italy). Total
Table 5: Restriction enzymes cutting frequency
Restriction 
enzyme name
Sequence 
cleaved
Number of Functional genes
TRAV TRBV TRDV TRGV TRAJ TRBJ TRDJ TRGJ TRBD TRDD TOTAL
(47) (54) (3) (9) (50) (14) (4) (5) (2) (3) (191)
A p a L I G T G C A C 120 00 0 000 0 3
AscI GGCGCGCC 000 00 0 000 0 0
BamHI GGATCC 7 7 0 0 0 0 0 0 0 0 14
B g l I I A G A T C T 240 00 0 000 0 6
BssHII GCGCGC 0 0 0 0 0 0 0 0 0 0 0
B s t E I I G G T N A C C 660 13 0 000 0 1 6
C l a I A T C G A T 01 10 00 0 000 0 1 1
EagI CGGCCG 0 3 0 0 0 0 0 0 0 0 3
EcoRI GAATTC 3 0 0 1 3 0 0 0 0 0 7
E c o R V G A T A T C 130 10 0 000 0 5
HaeIII (AG)GCGC(CT) 4 3 0 0 1 2 0 0 0 0 10
H i n d I I I A A G C T T 340 02 1 010 0 1 1
K p n I G G T A C C 72 61 70 0 000 0 4 1
NcoI CCATGG 3 4 0 0 0 0 0 0 0 0 7
NdeI CATATG 6 5 0 1 0 0 0 0 0 0 12
NheI GCTAGC 0 0 0 0 0 0 0 0 0 0 0
NotI GCGGCCGC 0 0 0 0 0 0 0 0 0 0 0
PstI CTGCAG 11 25 0 0 1 0 0 0 0 0 37
PvuI CGATCG 0 1 1 0 0 0 0 0 0 0 2
SacI GAGCTC 4 9 0 0 0 0 0 0 0 0 13
SacII CCGCGG 0 0 0 0 0 0 0 0 0 0 0
S a l I G T C G A C 000 00 0 000 0 0
SmaI CCCGGG 3 2 0 0 0 0 0 0 0 0 5
SpeI ACTAGT 1 0 0 0 0 0 0 0 0 0 1
SphI GCATGC 1 0 0 0 0 0 0 0 0 0 1
SfiI GGCCNNNNN
GGCC
000 00 0 000 0 0
XbaI TCTAGA 2 5 0 0 0 0 0 0 0 0 7
XhoI CTCGAG 0 1 0 0 0 0 0 0 0 0 1
Frequency of restriction enzymes cutting sites in human germline TR V, D and J genes. In bold the enzyme not cutting in any of the sequence 
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RNA was extracted from 1 × 106 cells using the E.Z.N.A.
Total RNA Kit I (Omega Bio-Tek Inc.). 600 ng of RNA was
reverse transcribed in a 40 μl reaction volume using the
Transcriptor High Fidelity cDNA Synthesis Kit (Roche
GmbH, Mannheim, Germany) and used as template for
PCR (0.5–1 μl of cDNA for each reaction in 25 μl reaction
volume). Common reverse primers were designed in the
constant region of the alpha, beta, gamma and delta
chains, and were located in the exon 1 of the respective
gene. Primers were designed in order to add a BssHII
restriction site on the forward and a NheI site on the
reverse primer, for further cloning purposes. Amplifica-
tions conditions were 30 s at 94°C, 30 s at 52°C, and 30
s at 72°C for 35 cycles. Primers used in this study are listed
in Table 1 (Biomers GmbH, Ulm, Germany). PCR prod-
ucts were gel-purified with the NucleoSpin Extract II kit
(Macherey-Nagel GmbH, Duren, Germany) and blunt-
cloned in the pTZ57R/T vector with the InsTAclone PCR
cloning Kit (Fermentas Inc, Vilnius, Lithuania).
Ligations were used to transform E. coli DH5α cells and
plated on LB/Amp/IPTG/X-gal plates for blue-white
screening. For each TR group, up to 13 random clones
were sequenced using a standard M13(-20) primer (5'-
GTAAAACGACGGCCAGTG-3').
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